NOAH: pCR Results Patients (%) P=0.002 P=0.003 P=0.29 P=0.43 With T

Slides:



Advertisements
Similar presentations
Neoadjuvant Hormone Treatment of Breast Cancer H.S.A. Oldenburg E.J.Th. Rutgers J.M. Dixon symposium 29 juni 2005.
Advertisements

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Time to Distant Metastases (ITT) Cumulative incidence of distant metastases (ITT) Adapted from Jones et al. SABCS 2008, abstract /477169/465253/454771/ /4146.
These slides were released by the speaker for internal use by Novartis.
Gianni L et al. Proc SABCS 2012;Abstract GS6-7.
Results grade1 grade2 grade3 (1) Can we identify metabolites or metabolic pathways that are associated with breast cancer clinical parameters? Alex-CIS-GCTOF.
Assistant Professor of Medicine Dana-Farber Cancer Institute
Neoadjuvant SystemicTreatment Strategies for Breast Cancer Donald W. Northfelt, MD, FACP Professor of Medicine Mayo Clinic College of Medicine Associate.
Neoadjuvant Endocrine Treatment in Breast Cancer Giorgio Mustacchi Centro Oncologico Università di Trieste.
Raised heart rate at discharge after acute heart failure is an independent mortality predictor.
Terapia Neoadiuvante Revisione delle evidenze scientifiche
The Role of mTOR in Cancer Etiology and Treatment Based on presentations from the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
Ο ρόλος των μη χειρουργικών θεραπειών στο μη μεταστατικό μυοδιηθητικό καρκίνο ουροδόχου κύστεως Γεώργιος Δ. Λύπας Παθολόγος Ογκολόγος Α’ Ογκολογική Κλινική.
Table S1: The results of ER, PgR, and HER2 status in IHC testing and mRNA expression in the full Consortium population (N=389) HER2 statusER status PgR.
CCO Independent Conference Coverage
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.
Patient #1 Patient #2 Patient #3 Normal Lung
Slamon D et al. SABCS 2009;Abstract 62.
Number of brain metastasis
Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive.
Cumulative Probability of Developing Colon Cancer in UC Patients
TRAIN-2 (BOOG ): Phase III Trial of Neoadjuvant Chemotherapy ± Anthracyclines With Dual HER2 Blockade in HER2+ EBC CCO Independent Conference Highlights*
CCO Independent Conference Highlights
CCO Independent Conference Coverage
Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus.
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Presented By Luca Malorni at 2017 ASCO Annual Meeting
CCO Independent Conference Coverage
MAP-tau expression in the Yale University Cohort
Rearrangements of Gene A and Gene B
CD25 expression is associated with unfavorable clinical outcome.
Fig. 2 LYM attractor metagene.
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
Untch M et al. Proc SABCS 2010;Abstract P
Baselga J et al. SABCS 2009;Abstract 45.
Presented By Mathias Rummel at 2016 ASCO Annual Meeting
The Road to Quality Improvement in HER2-Positive Breast Cancer
Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).
Distribution of intrinsic subtypes among TNBC and distribution of TNBC among basal-like breast cancer. Distribution of intrinsic subtypes among TNBC and.
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
Continuing Adjuvant Tamoxifen to 10 Years
Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.
Electromagnetic navigation image: the icon representing the locatable guide (arrow) can be seen 3 mm away from the centre of a small pulmonary nodule in.
A) Healthcare utilisation, b) short form (SF)-12 scores and c) work productivity and activity impairment in patients with asthma (▓) and diabetes (▪) in.
a) Mortality per time point (p<0
3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).
20-Year Risks of Breast-Cancer Recurrence
Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).
Fig. 4. Treatment algorithm for palliative systemic therapy
Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.
Optoacoustic Imaging and Gray-Scale US Features of Breast Cancers: Correlation with Molecular Subtypes Total external optoacoustic US feature scores of.
Table 1. Diagnostic methods for systemic fungal infection (n=70)
Fig. 2 LYM attractor metagene.
(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.
(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).
Tamoxifen-treated patients.
ORs estimates for ER breast cancer subtypes in postmenopausal women ccording to tertiles of sex steroid hormone and SHBG levels. ORs estimates for ER breast.
MRNA expression IL-1α, IL-1β, IL-1Ra, IL-1RtI, ER α, ER β, and PR was analyzed by RT-PCR as described in “Materials and Methods.” Representative gel electrographies.
Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.
Clustering analysis of DTC-associated genes.
MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.
Genomic determinants of response to cytotoxic chemotherapy.
The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.
PHOENIX I: PASI 75 Response After 12 Weeks
MYC and LYN are coexpressed and have interdependent clinical outcomes.
High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.
CD36 expression is coordinately regulated in multiple cellular compartments. CD36 expression is coordinately regulated in multiple cellular compartments.
PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.
Presentation transcript:

NOAH: pCR Results Patients (%) P=0.002 P=0.003 P=0.29 P=0.43 With T Without T HER2 negative With T Without T HER2 negative HER2 positive HER2 positive pCR Total pCR T=trastuzumab Adapted from Gianni et al. ASCO 2007, abstract 532.

ER Negative vs. Positive PgR Negative vs. Positive pCR According to Receptor Status Total pCR ER Negative vs. Positive PgR Negative vs. Positive HER2 negative, no H 16% 32% vs. 6% (P=0.0007) 26% vs. 6% (P=0.007) HER2 positive, no H 20% 22% vs. 17% (P=0.51) 23% vs. 12% (P=0.24) HER2 positive, H 39% 48% vs. 18% (P=0.002) 48% vs. 11% (P=0.006) Adapted from Eiermann et al. Eur J Cancer Suppl 2008;6(7):115, Abstract 228.